Guggenheim Lowers InflaRx (NASDAQ:IFRX) Price Target to $14.00

InflaRx (NASDAQ:IFRX) had its price target cut by research analysts at Guggenheim from $22.00 to $14.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Several other research firms have also weighed in on IFRX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a research note on Monday, December 29th. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of InflaRx in a research note on Tuesday, December 30th. Raymond James Financial reissued an “outperform” rating on shares of InflaRx in a report on Wednesday, December 31st. Finally, Leerink Partners reaffirmed a “market perform” rating and set a $2.00 price target (down from $5.00) on shares of InflaRx in a report on Wednesday, December 3rd. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $6.17.

InflaRx Price Performance

Shares of IFRX opened at $0.94 on Friday. InflaRx has a one year low of $0.71 and a one year high of $1.94. The company has a market cap of $63.69 million, a P/E ratio of -1.24 and a beta of 1.48. The firm has a 50 day simple moving average of $0.93 and a two-hundred day simple moving average of $1.14.

InflaRx (NASDAQ:IFRX) last issued its earnings results on Thursday, March 19th. The company reported ($0.17) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.17). The business had revenue of ($0.04) million during the quarter, compared to analyst estimates of $0.03 million. On average, analysts expect that InflaRx will post -1.04 earnings per share for the current fiscal year.

Hedge Funds Weigh In On InflaRx

Several large investors have recently bought and sold shares of IFRX. Cubist Systematic Strategies LLC grew its holdings in shares of InflaRx by 33.9% during the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after purchasing an additional 7,616 shares during the last quarter. Woodline Partners LP bought a new position in InflaRx in the 1st quarter valued at approximately $766,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in InflaRx by 158.3% during the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company’s stock worth $118,000 after buying an additional 91,927 shares during the period. Adage Capital Partners GP L.L.C. bought a new stake in InflaRx during the 2nd quarter worth approximately $262,000. Finally, Squarepoint Ops LLC grew its holdings in InflaRx by 29.1% during the 3rd quarter. Squarepoint Ops LLC now owns 188,523 shares of the company’s stock worth $253,000 after acquiring an additional 42,489 shares during the last quarter. 42.39% of the stock is currently owned by institutional investors.

Trending Headlines about InflaRx

Here are the key news stories impacting InflaRx this week:

• Positive Sentiment: Company highlights promising Phase 2a izicopan data, progress toward Phase 2b readiness in hidradenitis suppurativa (HS), plans for PK bridging in China, active collaborator discussions, and a spring Capital Markets Day to outline the development path—these clinical and strategic updates are the main near‑term catalysts. InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
• Positive Sentiment: Guggenheim maintained a Buy rating while lowering its price target from $22 to $14 — the cut reduces upside vs prior expectations but the firm still signals conviction in the story, which can support the stock. Guggenheim price target note (Benzinga)
• Positive Sentiment: HC Wainwright continues to carry a Buy rating with a $6 target and published near‑term EPS estimates (Q1 2026: -$0.14; Q2 2026: -$0.13), providing analyst support and a clear set of expectations for upcoming quarters. HC Wainwright estimates (MarketBeat)
• Neutral Sentiment: InflaRx reported Q4 EPS of ($0.17), which met consensus, reducing near‑term headline risk from the print itself. Press Release
• Neutral Sentiment: Market coverage and public filings (Business Insider / GlobeNewswire) provide a fuller corporate update on milestones and timelines; these items clarify strategy but do not immediately alter cash or clinical risk. InflaRx full‑year results (Business Insider)
• Negative Sentiment: Revenue remains negligible and the company reported revenue below estimates; InflaRx is still loss‑making with consensus full‑year EPS around -$1.04, underlining ongoing financing and execution risk. Zacks: Q4 loss, revenue miss
• Negative Sentiment: Cash, cash equivalents and marketable securities totaled €46.2M at 12/31/25, which the company says funds operations to mid‑2027 — this finite runway implies potential dilution or financing needs if clinical programs extend or expand. InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.